KOD vs CORT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KOD · Kodiak Sciences$97.17 ▼ 0.75%
CORT · Corcept Therapeutics$63.62 ▼ 2.09%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KOD +344.3%
- CORT -18.1%
Head to head
| Metric | KOD | CORT |
|---|---|---|
| Price | $97.17 | $63.62 |
| Change today | ▼ 0.75% | ▼ 2.09% |
| Market cap | $6.35B | $6.96B |
| Return, 3 months | +161.1% | -48.4% |
| Return, year to date | +247.5% | +82.8% |
| Return, 1 year | +367.8% | -17.7% |
| P/E (TTM) | – | 47.8 |
| P/B | 506.1 | 8.4 |
| P/E percentile vs own 5y | 0th | 69th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +64.0% |
| Net profit growth (YoY) | -7.8% | +544.6% |
| Gross margin | – | 98.5% |
| Operating margin | – | 11.5% |
| Net margin | – | 16.5% |
| Return on equity | -1,360.9% | 21.7% |
| Analyst target vs. price | +30.9% | +161.4% |
| Analyst buy share | 86% | 100% |
| RSI (14) | 52 | 21 |
| 30-day volatility | 81.3% | 78.5% |
| Max drawdown, 1 year | -36.2% | -63.5% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CORT is the largest of the group by market value.
- KOD has returned the most over the past year.
- CORT has been the calmest stock over the last 30 days.